Y-mabs therapeutics, inc. (YMAB)

CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss

-91,273

-81,028

-71,952

-59,456

-51,725

-43,274

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

233

166

0

0

0

-

-

-

-

Stock-based compensation

6,004

4,657

3,675

2,725

2,658

1,966

0

0

0

Foreign currency transactions

-17

-43

-119

-7

-131

-97

0

0

0

Changes in assets and liabilities:
Other current assets

1,301

1,158

-1,322

1,480

1,730

2,821

0

0

0

Other assets

137

182

130

56

51

187

0

0

0

Accounts payable

4,491

2,617

592

4,644

-106

1,261

0

0

0

Accrued liabilities and other

196

1,388

3,778

3,266

2,671

1,700

0

0

0

NET CASH USED IN OPERATING ACTIVITIES

-81,770

-73,497

-62,495

-50,288

-48,104

-41,229

0

0

0

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment

1,865

1,965

0

0

0

-

-

-

-

NET CASH USED IN INVESTING ACTIVITIES

-1,865

-1,965

0

0

0

-

-

-

-

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercised stock options

0

-

-

-

-

-

-

-

-

Payment of offering costs for private placement

-

-

-

-

-

1,002

0

0

0

NET CASH PROVIDED BY FINANCING ACTIVITIES

0

-

-

-

-

98,763

0

0

0

Effect of exchange rates on cash, cash equivalents and restricted cash

60

23

81

48

89

56

0

0

0

NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

51,499

59,265

-65,131

49,980

52,029

57,356

0

0

0

SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES
Property and equipment purchases in accounts payable

-

49

0

0

0

-

-

-

-

Right-of-use assets obtained in exchange for lease obligations

-

901

0

0

0

-

-

-

-

Deferred offering costs included in other assets and accounts payable and accrued liabilities and other

-

-

-

-

-

-

0

0

0